Function of N6‐methyladenosine modification in tumors
N Zhang, Y Zuo, Y Peng, L Zuo - Journal of oncology, 2021 - Wiley Online Library
N6‐Methyladenosine (m6A) modification is a dynamic and reversible methylation
modification at the N6‐position of adenosine. As one of the most prevalent …
modification at the N6‐position of adenosine. As one of the most prevalent …
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
M Kudo - International journal of clinical oncology, 2022 - Springer
Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma
in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and …
in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and …
Cabozantinib for the treatment of solid tumors: a systematic review
P Maroto, C Porta, J Capdevila… - … in medical oncology, 2022 - journals.sagepub.com
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
Background The combination of atezolizumab and bevacizumab (Atezo-Bev) has become
the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC) …
the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC) …
[HTML][HTML] Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-life cohort
F Finkelmeier, B Scheiner, C Leyh, J Best, TW Fründt… - Liver Cancer, 2021 - karger.com
Abstract Background and Aims: The multikinase inhibitor cabozantinib has been approved
for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and …
for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and …
Hepatotoxicity of small molecule protein kinase inhibitors for cancer
M Viganò, M La Milia, MV Grassini, N Pugliese… - Cancers, 2023 - mdpi.com
Simple Summary This review reports the risk and management of the hepatotoxicity of all the
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian …
G Cabibbo, B Daniele, M Borzio… - Digestive and Liver …, 2024 - Elsevier
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-
related death. The remarkable improvements in treating HCC achieved in the last years …
related death. The remarkable improvements in treating HCC achieved in the last years …
Cabozantinib for HCC treatment, from clinical back to experimental models
S Deng, A Solinas, DF Calvisi - Frontiers in oncology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide. Patients with early-stage HCC can be treated successfully with surgical resection …
worldwide. Patients with early-stage HCC can be treated successfully with surgical resection …
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
V Zanuso, L Rimassa, C Braconi - Hepatology, 2023 - journals.lww.com
Over the past years, there has been a remarkable advance in the systemic treatment options
for advanced HCC. The overall survival has gradually increased over time, with larger …
for advanced HCC. The overall survival has gradually increased over time, with larger …
Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good …
T Kuzuya, N Kawabe, M Ariga, E Ohno, K Funasaka… - Cancers, 2023 - mdpi.com
Simple Summary The combination of atezolizumab plus bevacizumab (Atz/Bev) is now
widely used in clinical practice as a first-line treatment for patients with advanced …
widely used in clinical practice as a first-line treatment for patients with advanced …